Natixis’s Integra LifeSciences IART Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-1
| Closed | -$18 | – | 1116 |
|
|
2024
Q3 | $18 | Buy |
+1
| New | +$23 | ﹤0.01% | 940 |
|
|
2024
Q2 | – | Sell |
-1
| Closed | -$35 | – | 1065 |
|
|
2024
Q1 | $35 | Hold |
1
| – | – | ﹤0.01% | 985 |
|
|
2023
Q4 | $44 | Hold |
1
| – | – | ﹤0.01% | 1013 |
|
|
2023
Q3 | $38 | Hold |
1
| – | – | ﹤0.01% | 958 |
|
|
2023
Q2 | $41 | Hold |
1
| – | – | ﹤0.01% | 995 |
|
|
2023
Q1 | $57 | Buy |
+1
| New | +$56 | ﹤0.01% | 961 |
|
|
2022
Q3 | – | Sell |
-23,487
| Closed | -$1.27M | – | 1115 |
|
|
2022
Q2 | $1.27M | Buy |
+23,487
| New | +$1.41M | ﹤0.01% | 771 |
|
|
2022
Q1 | – | Sell |
-9,000
| Closed | -$603K | – | 1236 |
|
|
2021
Q4 | $603K | Buy |
9,000
+958
| +12% | +$64.8K | ﹤0.01% | 1000 |
|
|
2021
Q3 | $551K | Sell |
8,042
-4,570
| -36% | -$323K | ﹤0.01% | 995 |
|
|
2021
Q2 | $861K | Buy |
12,612
+5,612
| +80% | +$397K | ﹤0.01% | 633 |
|
|
2021
Q1 | $484K | Hold |
7,000
| – | – | ﹤0.01% | 944 |
|
|
2020
Q4 | $454K | Buy |
+7,000
| New | +$377K | ﹤0.01% | 910 |
|
|
2020
Q2 | – | Sell |
-43,099
| Closed | -$1.93M | – | 795 |
|
|
2020
Q1 | $1.93M | Buy |
+43,099
| New | +$2.26M | 0.02% | 392 |
|
|
2019
Q4 | – | Sell |
-58,940
| Closed | -$3.54M | – | 891 |
|
|
2019
Q3 | $3.54M | Buy |
58,940
+14,373
| +32% | +$856K | 0.02% | 406 |
|
|
2019
Q2 | $2.49M | Sell |
44,567
-94,790
| -68% | -$4.88M | 0.02% | 418 |
|
|
2019
Q1 | $7.72M | Sell |
139,357
-16,449
| -11% | -$838K | 0.05% | 312 |
|
|
2018
Q4 | $7.03M | Buy |
155,806
+40,446
| +35% | +$2.22M | 0.06% | 273 |
|
|
2018
Q3 | $7.6M | Buy |
115,360
+3,598
| +3% | +$224K | 0.04% | 320 |
|
|
2018
Q2 | $7.2M | Buy |
111,762
+32,837
| +42% | +$2.03M | 0.04% | 333 |
|
|
2018
Q1 | $4.37M | Buy |
+78,925
| New | +$4.14M | 0.03% | 381 |
|
|
2017
Q4 | – | Sell |
-80,412
| Closed | -$4.06M | – | 992 |
|
|
2017
Q3 | $4.06M | Buy |
80,412
+24,468
| +44% | +$1.26M | 0.04% | 296 |
|
|
2017
Q2 | $3.05M | Buy |
55,944
+5,938
| +12% | +$284K | 0.03% | 287 |
|
|
2017
Q1 | $2.11M | Buy |
50,006
+43,338
| +650% | +$1.85M | 0.03% | 304 |
|
|
2016
Q4 | $286K | Buy |
+6,668
| New | +$271K | ﹤0.01% | 655 |
|
Other funds holding IART
RCMNY
Natixis's IART Position: Q4 2024 in Review
Natixis sold out of Integra LifeSciences (IART) in Q4 2024, closing a stake of 1 share — an estimated $18 sold.
Natixis first reported a position in IART in Q4 2016 and held it in 24 quarters. The position peaked at $7.72M in Q1 2019. 223 funds tracked by Wall St. Rank hold IART as of Q4 2024.
- Natixis reported no remaining Integra LifeSciences position as of Q4 2024 after selling out during the quarter.
- Natixis sold 1 Integra LifeSciences share in Q4 2024, an estimated $18.
- Natixis first reported a position in Integra LifeSciences in Q4 2016 and held it in 24 quarters.
- Natixis's Integra LifeSciences position peaked at $7.72M in Q1 2019.
- 223 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2024.
Based on Natixis's 13F filing for Q4 2024, filed 13 Feb 2025.